Posts by Mourabit Halima

To advance clinical oncology in China, enhance physicians’ diagnostic and research capabilities, and further promote the development and implementation of CSCO guidelines, the Chinese Society of Clinical Oncology (CSCO), together with the Beijing CSCO Clinical Oncology Research Foundation, co-hosted the 2026 CSCO Guidelines Conference in Harbin from April 24 to 25.

Myelodysplastic/myeloproliferative neoplasm (MDS/MPN) overlap syndromes are rare hematologic malignancies characterized by marked clinical heterogeneity and significant diagnostic and therapeutic challenges. Allogeneic hematopoietic stem cell transplantation remains a key treatment option; however, the lack of standardized criteria for assessing post-transplant remission and relapse represents a major unmet clinical need.

As a leading global academic organization in transplantation and cellular therapy, the European Society for Blood and Marrow Transplantation (EBMT) has long been committed to advancing clinical research, optimizing patient management, and fostering international collaboration. In the era of rapid progress in cell and gene therapies, EBMT is entering a new phase of opportunity.

Cord blood transplantation (CBT), an important modality within hematopoietic stem cell transplantation, has faced increasing competition in recent years from alternative donor strategies such as haploidentical transplantation. As a result, the field is undergoing a period of reassessment and transformation. Nevertheless, CBT retains irreplaceable value in selected patient populations, while its potential applications in cell and gene therapy as well as regenerative medicine continue to expand.

From April 10 to 11, 2026, the Annual Academic Meeting of the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care (CPAM), together with the “Huatuo Project” MDT Symposium, was held in Changsha. During the meeting, Professor Yajing Xu, Executive Chair and Director of Hematology at Xiangya Hospital, Central South University, was invited by Hematology Frontier to share her insights on the clinical challenges of long-term follow-up after hematopoietic stem cell transplantation (HSCT), standardized management models, and pathways for primary care collaboration. Her discussion aimed to promote the standardization of follow-up systems and improve long-term survival and quality of life for patients.